Posts Tagged: commercialization in Canada

UTEST named one of Canada’s seven true start-up accelerators

The University of Toronto Early-Stage Technology (UTEST) program,  part of U of T’s growing ecosystem of incubators and commercialization support services, has been named one of Canada's seven true start-up accelerators. The findings come from Helen Kula's MaRS Data Catalyst report and were covered by Rob Lewis of TechVibes. (more…) Read more

MaRS Discovery District launches MaRS EXCITE to help breakthrough technologies reach patients faster

MI start-up ApneaDx Inc. among program's first round of participants The first three companies selected to participate in the MaRS EXCITE program aim to improve outcomes for breast cancer, sleep apnea and drug-resistant hypertension. The Excellence in Clinical Innovation and Technology Evaluation (EXCITE) initiative helps companies accelerate the adoption and reimbursement of innovative health technologies through a single, harmonized, pre-market, evidence-based process. EXCITE has selected ApneaDx Inc., Medtronic of Canada Ltd. and Rna Diagnostics Inc. as the program’s initial participants. (more…) Read more

Five UTEST companies to tackle critical healthcare challenges

Program's second cohort includes eQOL, E-Twenty Development, Root2Crown, Treata Smart Solutions and TrendMD TORONTO (May 14, 2013) — Five companies tackling pervasive healthcare challenges — such as assessing dental health, helping patients and medical personnel navigate hospitals with greater ease, staying current with medical literature, or creating digital tools to help care for the elderly or those with chronic health conditions — have been admitted to the University of Toronto Early Stage Technology (UTEST) program’s second cohort. UTEST, supported by the University of ... Read more

Dr. Raphael Hofstein in Biotechnology Focus: Building a catalytic reaction across Canada’s Life Sciences Sector

Biotechnology Focus, a compendium of the Canadian life sciences industry, has published a guest column by MaRS Innovation President & CEO, Raphael Hofstein. The article explores the role of catalysis in building Canada's Life Sciences sector: In chemistry, according to Encyclopædia Britannica Online, a catalyst is any substance that increases a reaction’s rate without itself being consumed. Kinetically, Wikipedia tells us, catalytic reactions are typical chemical reactions where the reaction rate depends on the reactants’ frequency of contact in the rate-determining step. Usually, ... Read more

Canadian biotech sector makes strong showing at BIO2013

Every six weeks, MaRS Innovation's marketing and communications manager writes a guest post for the MaRS Discovery District blog profiling MI's activities or one of our start-up companies. You can read the original post on the MaRS blog. Nearly 14,000 delegates—representing over 1,100 biotechnology companies, academic institutions, state biotechnology centres and related organizations across the United States and more than 60 countries—attended the 2013 BIO International Convention from April 22 to 26, 2013. The event drew biotechnologists, pharmaceutical industry executives and life sciences researchers, ... Read more

How Canada’s health-care industry is riding a wave of transition

Bedside Clinical Systems featured on Research Innovation and Commercialization Centre (RICC) panel discussion In an article for YourMississaugaBiz.com, Jon Cook writes, " 'The health-care industry is relying more on the private sector for innovation and small businesses need to make sure they have a strong value proposition in order to get their projects funded,' said Telus Health executive Nicholas Zamora." The article describes a panel discussion organized by the Research Innovation and Commercialization Centre (RICC) on the "intersection of health care and technology ... Read more

MaRS Innovation announces new strategic partnership with Pfizer

TORONTO, April 22, 2013 — MaRS Innovation, a Centre of Excellence for Commercialization and Research, today announced the formation of a strategic partnership with Pfizer Inc. to advance early-stage technologies related to human health in therapeutics and diagnostics. Through this collaboration, MaRS Innovation and Pfizer will jointly identify investment opportunities emerging from well-validated scientific research discoveries within MaRS Innovation’s 16 member institutions, including the University of Toronto and its nine affiliated teaching hospitals. “There’s growing consensus that transferring technologies from the university lab ... Read more

Merck invests in pan-Canadian life sciences research innovation sector

A $4-million public-private partnership will promote research innovation involving three academic commercialization centres in Canada CHICAGO, Illinois – April 22, 2013 – Merck Canada will be announcing today at the BIO International Convention that it is reinforcing its commitment to the Canadian life sciences research innovation sector. Merck will provide $4 million in funding to the Institute for Research in Immunology and Cancer – Commercialization of Research (IRICoR) for future corridor projects developed in collaboration with two other Canadian Centres of Excellence for ... Read more

National Post: How does Canada solve its commercialization conundrum?

Government has key role to play as early-stage technology adopter says CEO Raphael Hofstein Dr. Raphael Hofstein, president and CEO of MaRS Innovation, was quoted in Mary Theresa Bitti's National Post article, "Commercialization Conundrum: Canada must turn ideas into social and economic value," published April 3, 2013. The article examines Canada's worsening track record in realizing commercialization gains based on the country's significant per-capita investment in R&D. Here's an excerpt: While Canada punches above its weight class when it comes to generating ideas — witness ... Read more

What does MaRS Innovation’s funding extension mean for Toronto’s academic entrepreneurs?

Every six weeks, MaRS Innovation's marketing and communications manager writes a guest post for the MaRS Discovery District blog profiling MI's activities or one of our start-up companies. You can read the original post on the MaRS blog. Created in 2008, MaRS Innovation (MI) bridges the chasm between the early-stage technologies emerging from its 16 member institutions and successful startup companies and licensable technologies. By offering early-stage funding in tandem with hands-on management, business development, mentorship and intellectual property protection strategy, MI acts as ... Read more
Page 9 of 12« First...7891011...Last »